HSBC raised the firm’s price target on Johnson & Johnson to $240 from $215 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Cautious Hold Rating for Johnson & Johnson Amid Promising Clinical Results and Competitive Challenges
- Carvykti strength holds, Legend Biotech weakness overdone, says RBC Capital
- Johnson & Johnson reports results from Phase 3 MajesTEC-3 study
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List
- Eli Lilly, Pfizer, Johnson secure spots on China’s drug catalog, Bloomberg says